Survodutide is investigational and licensed nowhere. The amounts below are protocol-defined trial doses reported as published evidence, not a schedule for anyone to follow. There is no approved product, no label, and no validated consumer regimen.
Overview
Survodutide is administered as a once-weekly subcutaneous injection, started low and escalated over several months to a target dose. Published trials have used weekly targets between 0.6 mg and 6.0 mg. No regulator has reviewed any of these, so none of them is "the dose" in the sense that word carries for an approved medicine.
The more instructive part of survodutide's dosing story is not the target number but the ramp used to reach it — a design element the developers themselves revised between phases.
The doses studied in trials
| Trial | Weekly doses | Escalation | Duration |
|---|---|---|---|
| Phase 2, obesity (n=386) | 0.6, 2.4, 3.6, 4.8 mg | 20 weeks | 46 weeks |
| Phase 2, MASH (n=293) | 2.4, 4.8, 6.0 mg | 24 weeks (rapid) | 48 weeks |
| SYNCHRONIZE-1, phase 3 (n=725) | up to 3.6 or 6.0 mg | protocol-defined, with provision for a prolonged period | 76 weeks |
The phase 2 obesity trial produced a clean dose-response — −6.2%, −12.5%, −13.2%, and −14.9% mean weight change across the four doses versus −2.8% on placebo (Lancet Diabetes Endocrinol 2024; PMID 38330987). Phase 3 then found that 6.0 mg gave essentially the same result as 3.6 mg (−13.0% versus −12.2%), while carrying more gastrointestinal burden (NEJM 2026; PMID 42253238). Higher is not automatically better, even within a compound's own programme.
Why escalation is the hard part
Every survodutide trial spends a third to a half of its duration simply getting participants to the target dose. That is not caution for its own sake: gastrointestinal adverse events cluster during the period when exposure is rising, and only 60.4% of participants completed the 46-week phase 2 treatment period.
The phase 3 protocol explicitly incorporated the possibility of a prolonged dose-escalation period into its primary analysis — an acknowledgement that people reach target at different rates and that the schedule has to bend. Glucagon receptor activity adds a second reason for the slow approach, since glycemic and cardiovascular parameters need observing at each step rather than being jumped past.
How it is administered
In trials, survodutide is supplied as a manufactured, pre-measured subcutaneous injection given once weekly; its extended duration of action is what permits weekly rather than daily dosing.
Research-grade powder is a categorically different situation. The delivered amount then depends on how much diluent was added at reconstitution and on reading syringe units as a volume — errors that multiply rather than add. Layered on top is the fact that a milligram figure from a trial protocol describes a characterised pharmaceutical product, not the contents of an unlabeled vial.
Why oversight matters
Survodutide acts on glucose through two receptors that pull in opposite directions, which makes its net effect impossible to reason about from either mechanism alone. In its trials, that balance is managed by protocol-defined escalation, scheduled laboratory monitoring, and investigators who can pause or reduce exposure. None of that infrastructure exists outside a study, and no approved labeling exists to replace it. The published dose figures are evidence about a supervised trial population — nothing more.